Last reviewed · How we verify

NCT07530640

Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities

Not yet recruiting Last updated 15 April 2026
What this trial tests

trial testing Atorvastatin-acute KD with CAA in Kawasaki Disease in 9 participants. Not yet recruiting.

Timeline
30 March 2026
Primary endpoint
31 August 2027
30 September 2027

Quick facts

Lead sponsorChildren's Hospital of Fudan University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment9
Start date30 March 2026
Primary completion31 August 2027
Estimated completion30 September 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Adults 2 to 18, any sex, with Kawasaki Disease or Coronary Artery Abnormalities. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about the safety and effects of atorvastatin in treatment of Chinese Kawasaki disease (KD) children complicated with coronary artery abnormalities (CAA) in acute phase. The main questions it aims to answer are: Is atorvastatin safe in Chinese children of acute KD? Does atorvastatin contribute to control the acute inflammation in KD and improve the CAA?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kawasaki Disease

Currently open trials in the same condition.

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07530640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing